a study in healthy adult male & female participants to assess the amount of the study medicine (sar443820) absorbed by the body, when given orally in fasted condition as a tablet versus as a capsule (part 1) and when given orally as a tablet in fasted condition versus as a tablet after food (part 2)

Conditions: Amyotrophic Lateral Sclerosis (Healthy Volunteers)

Summary: part 1: this is an open label, balanced randomized, single dose, 2-sequence, 2-period (period 1 and period 2), 2-treatment crossover (between treatment a and treatment b for part 1), study part to determine the relative bioavailability of sar443820 in tablet formulation versus capsule formulation under fasted conditions. two treatments are as follows: * treatment a: sar443820 - tablet formulation in fasted condition * treatment b: sar443820 - capsule formulation in fasted condition each administration will be a single dose of sar443820 separated by a wash out of at least 5 days. part 2: this is an open-label, balanced randomized, single dose, 2-sequence, 2-period (period 1 and period 2), 2-treatment crossover (between treatment c and treatment d for part 2) study part to perform a preliminary assessment of the effect of a high-fat meal on pharmacokinetic parameters of single dose of sar443820 in tablet formulation. two treatments are as follows: * treatment c: sar443820 - tablet formulation in fasted condition * treatment d: sar443820 - tablet formulation in fed condition each administration will be a single dose of sar443820 separated by a wash out of at least 5 days. participants are not allowed to participate in more than one part of the study. in both parts 1 and 2, the assessment of pharmacokinetic, safety and tolerability are performed at each treatment period at baseline (prior single dosing) up to 48-hour postdosing in healthy adult male and female participants.

screening period: up to 4 weeks (day -28 to day -2). in both part 1 and part 2: period 1: day -1 to day 3 and 5 days wash out period. period 2: day -1 to day 3 and until end-of-study visit at day 6.

Eligibility criteria:
inclusion criteria: * male or female participant must be 18 to 55 years of age inclusive, at the time of signing the informed consent * participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring * body weight between 50.0 and 100.0 kg, inclusive, if male, and between 40.0 and 90.0 kg, inclusive, if female, body mass index between 18.0 and 30.0 kg/m\^2, inclusive * all contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies * having given written informed consent prior to undertaking any study-related procedure exclusion criteria: * any history or presence of clinically relevant cardiovascular, pulmonary, gastrointestinal, hepatic, renal, metabolic, hematological, neurological, osteomuscular, articular, psychiatric, systemic, ocular, or infectious disease, or signs of acute illness * any medication (including st john's wort) within 14 days before inclusion or within 5 times the elimination half-life or pharmacodynamic half-life of the medication, with the exception of hormonal contraception or menopausal hormone replacement therapy; any non-live covid-19 vaccine within the last 2 weeks before randomization, any live attenuated vaccine within the last 28 days before randomization and any other non-vaccine biological drugs given within 4 months before randomization * positive result for hepatitis b, c or human immunodeficiency virus (hiv) * positive result on urine drug screen * positive urine alcohol test * positive severe acute respiratory syndrom coronavirus 2 (sars-cov-2) test * any consumption of citrus fruits (grapefruit, orange, etc) or their juices within 5 days before inclusion the above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.